Metastatic Melanoma Patients� Response to Immunotherapy can be Predicted With a Protein
Immunotherapy with PD-1 blockade is an effective treatment for many advanced cancers. PD-1 blockade makes cancer cells more vulnerable to attack by T cells.
Immunotherapy with PD-1 blockade is an effective treatment for many advanced cancers. PD-1 blockade makes cancer cells more vulnerable to attack by T cells.
‘Eltrapuldencel-T vaccine, derived from the patient’s own dendritic cells loaded with tumor proteins improved survival of patients with malignant melanoma.’
Tweet it Now
Robert O. Dillman, formerly Vice President Oncology, Caladrius Biosciences, Inc. and currently Chief Medical Officer, NeoStem Oncology (Irvine, CA) and Executive Medical and Scientific Director, Hoag Cancer Institute (Newport Beach, CA) discusses the typically poor prognosis for patients with melanoma of the eye or skin that spreads to the liver, and reports on the potential to achieve long-term survival without disease progression in a subset of patients using the eltrapuldencel-T vaccine.One patient had no disease progression for more than 4.5 years, while the other patient survived and remained disease-free for more than 12 years. The article "Long-term Progression-free and Overall Survival in Two Melanoma Patients Treated with Patient-Specific Therapeutic Vaccine Eltrapuldencel-T After Resection of a Solitary Liver Metastasis," provides a detailed discussion of the composition and use of the vaccine and its effectiveness in these patients.
"These exciting results illustrate the potential for melanoma patient-specific therapeutic vaccines to enhance long-term survival and add to the progress being made on the immmunotherapy of melanom," says Co-Editor-in-Chief Donald J. Buchsbaum, Department of Radiation Oncology, Division of Radiation Biology, University of Alabama at Birmingham.
Melanoma Patients Recieve Long-Term Benefit After Treatment With Nivolumab
The longest follow-up survival study conducted to date on patients with advanced melanoma who were treated with the PD-1 inhibitor nivolumab were reported.
The longest follow-up survival study conducted to date on patients with advanced melanoma who were treated with the PD-1 inhibitor nivolumab were reported.
Source-Eurekalert
Novel Immune Cell Appears to Block the Progress of Melanoma
Measuring tumor-derived extracellular vesicles (tEVs) levels can be used to predict treatment response, but assessing the impact of tEVs is difficult.
Measuring tumor-derived extracellular vesicles (tEVs) levels can be used to predict treatment response, but assessing the impact of tEVs is difficult.
SPF30 Sunscreens Delay Onset of Melanoma in Mouse Model
Sunscreens prevent skin from burning when exposed to UV sunlight, which is a major risk factor for melanoma. The SPF30 sunscreens were found to delay melanoma.
Sunscreens prevent skin from burning when exposed to UV sunlight, which is a major risk factor for melanoma. The SPF30 sunscreens were found to delay melanoma.
